MYGN — Myriad Genetics Income Statement
0.000.00%
Last trade - 00:00- $428.27m
- $398.57m
- $824.50m
Annual income statement for Myriad Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 691 | 678 | 753 | 838 | 825 |
| Cost of Revenue | |||||
| Gross Profit | 493 | 476 | 517 | 585 | 577 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 741 | 819 | 1,011 | 959 | 1,212 |
| Operating Profit | -50 | -141 | -257 | -121 | -387 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -57.1 | -141 | -262 | -124 | -395 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -24.5 | -112 | -263 | -127 | -366 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -27.2 | -112 | -263 | -127 | -366 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -27.2 | -112 | -263 | -127 | -366 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.948 | -1.25 | -2.23 | -1.17 | -1.71 |